Duo Oncology

Duo Oncology is a private, preclinical-stage biotech founded in 2020, headquartered in Cambridge, MA. The company is developing a proprietary nanomedicine platform that mimics DNA self-assembly to create exceptionally small particles capable of deep tumor penetration and environmentally triggered drug release. Led by an experienced team of oncologists and pharmaceutical scientists, Duo is building a pipeline of combination therapies targeting high-unmet-need cancers, supported by non-dilutive funding like an NCI STTR grant. Its core value proposition is overcoming stromal barriers to deliver potent drug combinations precisely where needed.

Proprietary nanomedicine platform that mimics DNA self-assembly to create ultrasmall, tumor-responsive nanoparticles. The platform enables the co-delivery of a duo of anti-cancer drugs, with environmentally sensitive bonds that trigger drug release specifically within the tumor microenvironment.

Duo competes in the next-generation nanomedicine space, aiming to improve upon first-generation nanoparticles like Abraxane with smaller size and smarter release. Competitors include other biotechs developing stimuli-responsive nanoparticles and novel drug delivery platforms. Key differentiators are the clinician-founded approach, ultrasmall particle size, and focus on dual-drug payloads for stroma-rich tumors.